Mereo BioPharma welcomes Dr. Abdul Mullick to its Board of Directors

– UK, London –  Mereo BioPharma Group plc (LON: MPH | NASDAQ: MREO), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to its Board of Directors, effective immediately.

Dr. Mullick joins Mereo’s Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases.

“We are very excited to welcome Abdul to the Board at such a pivotal time for the Company. His experience in the rare disease space and leadership while launching two new rare disease products will be invaluable to Mereo as we continue to advance our programs through the clinic. I believe Abdul will be an asset to the Board and very much look forward to working with him,” said CEO, Dr. Denise Scots-Knight.

About Dr. Abdul Mullick

Dr. Mullick currently serves as President and CEO of Kyowa Kirin International plc, a subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) the Japan-based global specialty pharmaceutical company. During his four years at KKI, Dr. Mullick successfully led the launch of two new rare disease products across Europe, the GCC1, and other growth markets, including for the treatment of X-linked hypophosphatemia, a disease characterized by low levels of phosphate in the blood. He also led a drive to enhance patient and customer care, resulting in improved profitability, as well as accelerating the digital transformation across the entire value chain. Before KKI, Dr. Mullick held senior positions at Vifor Pharma Ltd. as Head of Global Strategic Marketing, Novartis as Global Head of the Diabetes Franchise, and at Sanofi where he held roles in the country, regional and global levels. Most notably, he spent over eight years at Genzyme leading rare and ultra-rare disease businesses in Europe, Asia (including China and Japan), and the United States, as well as heading the rare disease global strategy and marketing function.

“Mereo has shown outstanding commitment to helping underserved patient populations and I am honored to be joining the Board,” said Dr. Mullick. “It is a very exciting time to be joining Mereo, as the Company has made tremendous strides in progressing its programs. I have seen first-hand the difference that innovation in treatments for rare diseases can make, especially where there are no existing approved therapies. I believe that Mereo’s late-stage assets have the potential to make a difference in the lives of patients and look forward to working with the team.”

Dr. Mullick graduated with a Ph.D. in Molecular Biology from Bristol University in the UK.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics that aim to improve outcomes for oncology and rare diseases and plans to commercialize selected rare disease programs. The Company has developed a portfolio of six clinical-stage product candidates. Mereo’s lead oncology product candidate, etigilimab, has advanced into an open-label Phase 1b/2 basket study evaluating anti-TIGIT in combination with an anti-PD-1 in a range of tumor types including three rare tumors and three gynecological carcinomas, cervical, ovarian, and endometrial carcinomas. The Company’s second oncology product, navicixizumab, for the treatment of late line ovarian cancer, has completed a Phase 1 study and has been partnered with OncXerna Therapeutics, Inc., formerly Oncologie, Inc. The Company has two rare disease product candidates, alvelestat for the treatment of severe Alpha-1 antitrypsin deficiency and Bronchiolitis Obliterans Syndrome, and setrusumab for the treatment of osteogenesis imperfecta (OI). Alvelestat has received U.S. Orphan Drug Designation for the treatment of AATD and positive top-line data were recently reported from a Phase 2 proof-of-concept study in North America, Europe, and the UK. The Company’s partner, Ultragenyx Pharmaceutical, Inc., has initiated a pivotal Phase 2/3 pediatric study in young adults (5-25 years old) for setrusumab in OI and expects to initiate a study in pediatric patients (2-5 years old) in the second half of 2022.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team